QMS Medical Allied Services Limited β Q2FY27 earnings call summary
Filed 21 November 2026 Β· Official transcript
- EBITDA Q2 FY27 at INR6.5 Cr (12.4% margin); H1 FY27 EBITDA INR14.8 Cr (13.6% margin); PAT Q2 at INR2.4 Cr, H1 at INR6.4 Cr
- FY27 revenue guidance INR210-220 Cr; EBITDA guidance deferred pending Q3 results
- Q2 FY27 revenue grew 17.5% y-y to INR52.5 Cr; H1 FY27 revenue up 20% to INR109.4 Cr
- Services vertical targets INR180 Cr revenue in FY27 with 20-25% CAGR; merger with HCAH to create larger PSP platform
- Synergies from PSP merger expected operationally in FY28; legal approvals to take 12-13 months
- Employee expenses rose due to investments in people and technology; incremental costs backed by contracts
- Products vertical signed 5-year exclusive distribution with HEINE starting Jan 2027; aims to double HEINE revenue in 5 years
- BeamOptics acquisition to build indigenous R&D and manufacturing capabilities; transaction valuation pending
Open source transcript Β· View QMS Medical Allied Services Limited research
Sign in free to track QMS Medical Allied Services Limited and receive future summaries.